Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.
Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.